AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King?

AbbVie announced a $10.9 billion acquisition of clinical-stage biotech Apogee Therapeutics, paying $135.11 per share in cash. The deal strengthens AbbVie's immunology portfolio with access to promising drug candidates like zumilokibart for eczema and asthma. While the acquisition will create near-term EPS headwinds, analysts expect it to be accretive by 2032 and support AbbVie's dividend yield of over 3%.

06/22/2026, 6:36 PM • The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

06/22/2026, 1:47 PM • GlobeNewswire

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares (~$1.5 million) on March 11, 2026, representing 1.71% of his holdings. The sale was executed under a Rule 10b5-1 plan, suggesting it reflects a pre-planned strategy rather than negative sentiment. Despite the insider sale, the company's stock has surged nearly 100% in the past year. The article emphasizes that investors should focus on Apogee's positive Phase 2 clinical data showing 85% patient response durability, upcoming Phase 3 trials, and a $350 million equity offering that strengthens its balance sheet for late-stage development.

03/26/2026, 11:33 AM • The Motley Fool

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics priced an underwritten public offering of 5 million shares at $70 per share, raising approximately $350 million in gross proceeds. The offering is expected to close on March 26, 2026. The company is a clinical-stage biotech firm developing novel biologics for inflammatory and immunology markets, with its lead program Zumilokibart (APG777) in development for atopic dermatitis, asthma, and eosinophilic esophagitis.

03/24/2026, 9:53 PM • GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

Apogee Therapeutics announced it will report 52-week Phase 2 APEX trial data for zumilokibart (APG777) in atopic dermatitis patients on March 23, 2026, via conference call at 8:00 a.m. ET. The company is advancing novel biologics targeting inflammatory and immunology markets.

03/22/2026, 7:51 PM • GlobeNewswire

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million

Great Point Partners increased its stake in Apogee Therapeutics (APGE) by 70,000 shares to 374,000 shares worth $28.23 million, making it the fund's largest holding at 9.15% of assets. APGE stock has doubled over the past year and is advancing monoclonal antibody therapies for inflammatory diseases with Phase 2 atopic dermatitis data expected in H1 2026.

02/25/2026, 3:06 PM • The Motley Fool

Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

Apogee Therapeutics reported positive interim Phase 1b results for zumilokibart (APG777), its anti-IL-13 antibody, in mild-to-moderate asthma patients, demonstrating rapid and durable suppression of FeNO biomarker through 16 weeks with a favorable safety profile. The company also highlighted multiple anticipated 2026 milestones including Phase 2 APEX data readouts in atopic dermatitis and potential Phase 3 initiation by late 2026, with a strong cash position of $913 million supporting operations into H2 2028.

01/06/2026, 6:00 AM • GlobeNewswire

Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody

Apogee Therapeutics reported positive Phase 1 trial results for APG333, a novel half-life extended TSLP antibody, demonstrating a 55-day half-life and potential for quarterly dosing in respiratory treatments.

11/10/2025, 7:00 AM • GlobeNewswire

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

Apogee Therapeutics successfully closed a public offering of 8,048,782 shares and pre-funded warrants, raising approximately $345 million to advance its clinical-stage biologics in inflammatory and immunology markets.

10/10/2025, 4:01 PM • GlobeNewswire

Why Apogee Therapeutics Stock Triumphed on Thursday

Apogee Therapeutics, a clinical-stage biotech company, announced a secondary stock offering of approximately 6.95 million shares at $41 per share, potentially raising around $300 million for preclinical studies, clinical trials, and research and development activities.

10/09/2025, 5:26 PM • The Motley Fool

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

Apogee Therapeutics is conducting a public offering of 6,951,221 common stock shares and pre-funded warrants, expecting to raise approximately $300 million to support its clinical-stage biologics development.

10/08/2025, 9:52 PM • GlobeNewswire

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics reported positive 16-week data from its Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial showed 71% reduction in EASI score and 66.9% of patients achieving EASI-75 response, with a favorable safety profile.

07/07/2025, 6:00 AM • GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics will report 16-week data from its Phase 2 APEX trial for APG777, a potential treatment for atopic dermatitis, on July 7, 2025, with a conference call and webcast to discuss the results.

07/06/2025, 6:00 PM • GlobeNewswire